Health TrialsbyHealthPanel

ALK+ Non-Small-Cell Lung Carcinoma

2

Review clinical trials related to ALK+ Non-Small-Cell Lung Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Participants needed: 54
Trial details
Phase: Phase 1Biological sex: AllType: InterventionalSponsor: Nuvectis Pharma, Inc.Updated: Aug 25, 2026Locations: 1
Eligibility criteria

18 years old or older [+4]

Known single or compound ALK domain mutations that cause resistance to lorlatini... [+1]

Read more
Status: Recruiting

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context

Participants needed: 90
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: PfizerUpdated: May 6, 2026Locations: 31
Eligibility criteria

Patients (male or female) 18 years of age or older at age inclusion [+3]

Evidence of active malignancy within the last 2 years prior to inclusion (other... [+16]

Read more